OBJECTIVE - To investigate whether advanced glycation end products (AGEs) p
articipate in the development of coronary artery disease (CAD) in nondiabet
ic and diabetic subjects.
RESEARCH DESIGN AND METHODS - Serum concentrations of AGEs were measured us
ing a newly established enzyme-linked immunosorbent. assay in 48 nondiabeti
c patients (normal glucose tolerance, n = 20; impaired glucose tolerance, n
= 28) who received coronary angiography for the study of chest pain or sus
pected CAD. Insulin sensitivity was examined by the euglycemic-hyperinsulin
emic glucose clamp technique and was estimated as the mean glucose infusion
rate during the last 30 min of clamp time (M value).
RESULTS- Patients were classified into four groups based on the number of s
ignificantly stenosed vessels, defined as 0-, 1-, 2-, or 3-vessel disease.
Serum concentrations of AGEs were significantly higher in nondiabetic subje
cts with CAD than in control subjects (2.42 +/- 0.65 vs. 1.96 +/- 0.40 mU/m
l, P < 0.01) and significantly correlated with the number of significantly
stenosed vessels (r = 0.678, P < 0.001). M values significantly inversely c
orrelated with serum concentrations of AGEs (r = -0.490, P < 0.05). In mult
iple regression analysis, with the number of significantly, stenosed Vessel
s as the dependent variable, serum concentrations of AGEs. 2-h plasma gluco
se, and areas under the plasma glucose response curve were independently as
sociated.
CONCLUSIONS - This pilot study indicates the relation between AGEs and the
severity of CAD in nondiabetic patients. The measurement of serum AGE conce
ntrations may be predictive of vascular damage.